KCT0007744尚未招募未知
A multicenter, open-label, randomized prospective study to compare the haemostatic effect of Clear Coajet during Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 404
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 85(Year)（—）
- 性别
- All
入选标准
- •(1) Men and women between the ages of 18 and 85
- •(2) A sessile polyp larger than 1.5 cm or a lateral spreading tumor, that is decided to perform endoscopic mucosal resection or endoscopic submucosal dissection
- •(3) A person who has signed a written informed consent form to participate in this study
排除标准
- •(1) Pedunculated polyp
- •(2) Patients with Coagulopathy (international normalized ratio >1.5, a partial thromboplastin time >45 s, or a platelet count <80,000/mL)
研究者
相似试验
进行中（未招募）
1 期
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimensMedDRA version: 19.1Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2015-004985-27-NLHOVON Foundation
招募中
2 期
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of Gazyvaro (obinutuzumab) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens. (GIVE trial)10024324Chronic Lymphocytic LeukemiaCLLNL-OMON54803HOVO70
已完成
4 期
A study to compare the effectiveness of Alpecin liquid & Minoxdil 5% in the management of male pattern baldness(Hair loss).CTRI/2014/07/004768Fullife Healthcare Pvt Ltd210
进行中（未招募）
1 期
A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic kidney cancer (BERAT study)metastatic renal cell carcinoma (mRCC)MedDRA version: 18.0Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2011-005939-78-DECESAR Central European Society for Anticancer Drug Research-EWIV
进行中（未招募）
不适用
A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappearance of T2 after rocuronium or vecuronium in Japanese and Caucasian subjects. Part B: Caucasian subjects.ot applicableEUCTR2005-001133-15-DEV Organon100